ZEO ScientifiX Partners with National Provider of Healthcare Services
ZEO ScientifiX (OTCQB:ZEOX) has partnered with Physicians Group, , a multi-state provider organization operating 75 clinics with over 750 clinical personnel. This collaboration aims to advance clinical trials for ZEO's products, focusing on health indications commonly seen by Physicians Group's doctors. The partnership provides ZEO with access to a diverse patient population and experienced clinicians for potential trial enrollment.
ZEO recently completed successful Phase 1 trials of its flagship product, Zofin™, and is now preparing for Phase 2 trials for multiple indications. The company's goal is to obtain FDA approval for its products in treating various diseases and chronic conditions. Physicians Group, founded over 25 years ago, has treated more than 150,000 patients and specializes in neck, back, and extremity injuries.
ZEO ScientifiX (OTCQB:ZEOX) ha stretto una collaborazione con Physicians Group, un'organizzazione multi-statale che gestisce 75 cliniche con oltre 750 personale clinico. Questa collaborazione ha l'obiettivo di avanzare i trial clinici per i prodotti di ZEO, concentrandosi sulle indicazioni di salute comunemente osservate dai medici di Physicians Group. La partnership fornisce a ZEO accesso a una popolazione di pazienti diversificata e clinici esperti per un potenziale reclutamento nei trial.
ZEO ha recentemente completato con successo i trial di Fase 1 del suo prodotto di punta, Zofin™, e ora si sta preparando per i trial di Fase 2 per molteplici indicazioni. L'obiettivo dell'azienda è ottenere l'approvazione della FDA per i suoi prodotti nel trattamento di varie malattie e condizioni croniche. Physicians Group, fondata oltre 25 anni fa, ha trattato più di 150.000 pazienti ed è specializzata in infortuni al collo, schiena e estremità.
ZEO ScientifiX (OTCQB:ZEOX) se ha asociado con Physicians Group, una organización proveedora multimunicipal que opera 75 clínicas con más de 750 personal clínico. Esta colaboración tiene como objetivo avanzar en los ensayos clínicos de los productos de ZEO, centrándose en indicaciones de salud comúnmente vistas por los médicos de Physicians Group. La asociación proporciona a ZEO acceso a una población de pacientes diversa y clínicos experimentados para la posible inscripción en ensayos.
ZEO ha completado recientemente con éxito los ensayos de Fase 1 de su producto insignia, Zofin™, y ahora se está preparando para los ensayos de Fase 2 para múltiples indicaciones. El objetivo de la empresa es obtener la aprobación de la FDA para sus productos en el tratamiento de varias enfermedades y condiciones crónicas. Physicians Group, fundada hace más de 25 años, ha tratado a más de 150,000 pacientes y se especializa en lesiones de cuello, espalda y extremidades.
ZEO ScientifiX (OTCQB:ZEOX)는 750명 이상의 임상 인력을 보유한 75개의 클리닉을 운영하는 다주 주 의료 제공 조직인 Physicians Group과 협력했습니다. 이 협력은 ZEO 제품에 대한 임상 시험을 발전시키는 것을 목표로 하며, Physicians Group의 의사가 일반적으로 다루는 건강 지표에 초점을 맞춥니다. 이 파트너십은 ZEO에 다양한 환자 집단과 잠재적인 시험 등록을 위한 경험이 풍부한 임상 의사에 대한 접근을 제공합니다.
ZEO는 최근 자사의 주력 제품 Zofin™의 1상 시험을 성공적으로 완료했으며, 이제 여러 가지 적응증에 대한 2상 시험을 준비하고 있습니다. 회사의 목표는 다양한 질병 및 만성 질환 치료를 위한 제품에 FDA 승인을 받는 것입니다. 25년 이상된 Physicians Group은 150,000명 이상의 환자를 치료했으며, 목, 허리 및 팔다리 부상을 전문으로 하고 있습니다.
ZEO ScientifiX (OTCQB:ZEOX) a établi un partenariat avec Physicians Group, une organisation de prestataires multi-états exploitant 75 cliniques avec plus de 750 personnel clinique. Cette collaboration vise à faire progresser les essais cliniques pour les produits de ZEO, en se concentrant sur les indications de santé couramment observées par les médecins de Physicians Group. Le partenariat offre à ZEO un accès à une population de patients diversifiée et à des cliniciens expérimentés pour un éventuel recrutement dans les essais.
ZEO a récemment terminé avec succès les essais de Phase 1 de son produit phare, Zofin™, et se prépare maintenant aux essais de Phase 2 pour plusieurs indications. L'objectif de l'entreprise est d'obtenir l'approbation de la FDA pour ses produits dans le traitement de diverses maladies et conditions chroniques. Physicians Group, fondée il y a plus de 25 ans, a traité plus de 150 000 patients et est spécialisée dans les blessures au cou, au dos et aux membres.
ZEO ScientifiX (OTCQB:ZEOX) hat sich mit Physicians Group zusammengeschlossen, einer überstaatlichen Anbieterorganisation, die 75 Kliniken mit über 750 klinischen Mitarbeitern betreibt. Diese Zusammenarbeit zielt darauf ab, klinische Studien für ZEOs Produkte voranzutreiben, wobei der Fokus auf Gesundheitsindikationen liegt, die häufig von den Ärzten der Physicians Group behandelt werden. Die Partnerschaft ermöglicht ZEO den Zugang zu einer vielfältigen Patientenschaft und erfahrenen Kliniker für die mögliche Studienanmeldung.
ZEO hat kürzlich erfolgreiche Phase-1-Studien seines Hauptprodukts Zofin™ abgeschlossen und bereitet sich nun auf Phase-2-Studien für mehrere Indikationen vor. Das Ziel des Unternehmens ist es, die FDA-Zulassung für seine Produkte zur Behandlung verschiedener Krankheiten und chronischer Erkrankungen zu erhalten. Physicians Group, die vor über 25 Jahren gegründet wurde, hat mehr als 150.000 Patienten behandelt und ist auf Verletzungen von Nacken, Rücken und Extremitäten spezialisiert.
- Partnership with Physicians Group provides access to 75 clinics and 750+ clinical personnel
- Successful completion of Phase 1 clinical trials for flagship product Zofin™
- Preparation for Phase 2 trials of Zofin™ for multiple indications
- Access to diverse patient population and experienced clinicians for potential trial enrollment
- Regenerative medicine market expected to grow to $175 billion by 2032 with 22.8% annual growth rate
- None.
Physicians Group, LLC's Network Of Clinics And Diverse Patient Population Will Provide ZEO With Exclusive Research-Based Opportunities
FORT LAUDERDALE, FL / ACCESSWIRE / October 1, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company, announced that it has recently partnered with Physicians Group, LLC ("Physicians Group"), a multi-state provider organization that together with its affiliated entities operates 75 clinics and employees over 750 clinical personnel treating between 1,500 - 2,000 patients per month, many of whom seek care for musculoskeletal conditions.
ZEO and Physicians Group intend to collaborate on future clinical trials that will focus on certain health indications commonly seen by Physicians Group's doctors whereby ZEO's products demonstrate greater therapeutic benefit than currently available treatments.
"This partnership marks a pivotal moment for us," reflected Ian Bothwell, Interim Chief Executive Officer and Chief Financial Officer at ZEO ScientifiX. "With Physicians Group's support, we can take advantage of both our companies' strengths. Physicians Group's large network of doctors and its diverse patient population significantly increase the number of opportunities to advance our research objectives and provide our therapeutics to patients who may benefit. In addition, our partnership gives us access to highly informed and experienced clinicians as well as potentially qualified subjects for enrollment in ZEO's planned clinical trials."
ZEO's research and development (R&D) product pipeline reflects the Company's commitment to innovation and its mission to advance the use of biologic therapies to address the unmet needs of patients facing acute and chronic conditions in multiple areas.
ZEO recently completed successful Phase 1 clinical trials involving its flagship proprietary product, Zofin™. Now, the Company is actively seeking to launch Phase 2 trials of Zofin™ for several indications, along with clinical trials for other products in the Company's pipeline. ZEO's goal is to obtain FDA approval for the use of its products for the treatment of various diseases and chronic conditions.
Founded in Florida more than 25 years ago, today, Physicians Group operates nationally and has treated more than 150,000 patients, earning a reputation for excellence in the treatment of neck, back, and extremity injuries.
"There are many reasons why ZEO ScientifiX was the right company for our partnership," reflected Rob Adams, Chief Executive Officer at Physicians Group. "We have been extremely impressed by ZEO's facilities, management team, and strong commitment to research and science. Moreover, this partnership will offer our clinical team the opportunity to access leading-edge therapeutics to support the treatment of our patients." According to Precedence Research, the regenerative medicine space is expected to grow to a nearly
For more information, or to schedule an interview, please contact Meieli Sawyer at msawyer@weinbachgroup.com or 305-668-0070.
About ZEO ScientifiX, Inc.
ZEO ScientifiX, Inc. (OTCQB:ZEOX) is a clinical-stage biopharmaceutical company located at Nova Southeastern University's Collaborative Center for Research. ZEO primarily focuses on the development of innovative biological therapeutics for the treatment of chronic diseases and the provision of related services. The Company's proprietary products are derived from allogenic and autologous sources and are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit https://zeoscientifix.com/
Forward-Looking Statements
Certain statements contained in this press release, including those regarding the impact of the partnership with Physicians Group should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Company will be successful in its research initiatives. In addition, no assurances can be given that our research initiatives will increase the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
###
Contact Information
Meieli Sawyer
Director of Communications
msawyer@weinbachgroup.com
305-668-0070
SOURCE: ZEO ScientifiX, Inc.
View the original press release on accesswire.com
FAQ
What is the new partnership announced by ZEO ScientifiX (ZEOX)?
What stage of clinical trials has ZEO ScientifiX (ZEOX) completed for its product Zofin™?
What are ZEO ScientifiX's (ZEOX) plans for future clinical trials?
How many patients has Physicians Group treated since its founding?
